ChemGenex Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
At the moment, chemical genomics is discussed mostly as a hot new approach to drug discovery. Dennis Brown, the founder of ChemGenex Therapeutics Inc. thinks the approach can be applied right now to improve preclinical and clinical drug development--specifically for cancer drugs. His firm is harnessing new methods including gene expression analysis, cellular arrays and information technology to find and assess compounds that already exist. The firm is also leveraging Brown's Rolodex to inform its bioinformatics software. It's gathering insights and tips from medicinal chemists and academic oncologists who've been working with cancer drugs for decades.
You may also be interested in...
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.